GH receptor isoforms and skeletal fragility in acromegaly

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages 237-245

  Mormando, Marilda ^a   Nasto, Luigi A ^a   Bianchi, Antonio ^a   Mazziotti, Gherardo ^b   Giampietro, Antonella ^a   Pola, Enrico ^a   Pontecorvi, Alfredo ^a   Giustina, Andrea ^b   De Marinis, Laura ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EXON; FEMALE; FEMUR; FL GENE; GENDER; GENE; GENE DELETION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GHR GENE; HETEROZYGOTE; HIP; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SPINE FRACTURE;

ACROMEGALY; ADULT; AGED; BONE DENSITY; CROSS-SECTIONAL STUDIES; EXONS; FEMALE; GENE DELETION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; ITALY; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RECEPTORS, SOMATOTROPIN; SPINAL FRACTURES;

EID: 84905215549     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0205     Document Type: Article

References (46)

1. Giustina A, Mazziotti G & Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocrine Reviews 2008 29 535-559. (doi:10.1210/er.2007-0036)
2. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z & Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. PNAS 1989 86 8083-8087. (doi:10.1073/pnas. 86.20.8083)
3. Urbanek M, MacLeod JN, Cooke NE & Liebhaber SA. Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor gene transcript. Molecular Endocrinology 1992 6 279-287. (doi:10.1210/mend.6.2.1569971)
4. Sobrier ML, Duquesnoy P, Duriez B, Amselem S & Goossens M. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Letters 1993 319 16-20. (doi:10.1016/0014-5793(93)80028-S)
5. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V & Bougnères P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genetics 2004 36 720-724. (doi:10.1038/ng1379)
6. Binder G, Baur F, Schweizer R & Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. Journal of Clinical Endocrinology and Metabolism 2006 91 659-664. (doi:10.1210/jc.2005- 1581)
7. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB & Arnhold IJ. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 2006 91 1076-1080. (doi:10.1210/jc.2005-2005)
8. Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE & Wiesli P. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clinical Chemistry 2007 53 1484-1488. (doi:10.1373/clinchem.2007.085712)
9. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A & De Marinis L. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 2015-2022. (doi:10.1210/jc.2008-1337)
10. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A & De Marinis L. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 2009 12 196-199. (doi:10.1007/s11102-008-0157-8)
11. Kholer S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS, Wiesli P & Schmid C. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and Comparative Endocrinology 2013 188 282-287. (doi:10.1016/j.ygcen.2013.04.024)
12. Turgut S, Akin F, Ayada C, Topsakal S, Yerlikaya E & Turgut G. The growth hormone receptor polymorphism in patients with acromegaly: relationship to BMI and glucose metabolism. Pituitary 2012 15 374-379. (doi:10.1007/s11102- 011-0329-9)
13. Wassenaar MJ, Biermasz NR, Pereira AM, van der Klaauw AA, Smit JW, Roelfsema F, van der Straaten T, Cazemier M, Hommes DW, Kroon HM et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 4671-4678. (doi:10.1210/jc.2009-1172)
14. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L & Giustina A. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. Journal of Bone and Mineral Research 2005 20 1837-1844. (doi:10.1359/JBMR.050603)
15. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L & Giustina A. Prevalence of vertebral fractures in men with acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 4649-4655. (doi:10.1210/jc.2008-0791)
16. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L & Giustina A. Vertebral fractures in patients with acromegaly: a 3 year prospective study. Journal of Clinical Endocrinology and Metabolism 2013 98 3402-3410. (doi:10.1210/jc.2013-1460)
17. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jcem.85.2.6363)
18. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S et al. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
19. Boquete HR, Sobrado PG, Fideleff HL, Sequera AM, Giaccio AV, Suárez MG, Ruibal GF & Miras M. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. Journal of Clinical Endocrinology and Metabolism 2003 88 4702-4708. (doi:10.1210/jc.2003- 030412)
20. Griffith JF & Genant HK. New advances in imaging osteoporosis and its complications. Endocrine 2012 42 39-51. (doi:10.1007/s12020-012-9691-2)
21. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D & Cummings SR. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research 1996 11 984-996. (doi:10.1002/jbmr.5650110716)
22. Crans GG, Genant HK & Krege JH. Prognostic utility of a semiquantitative spinal deformity index. Bone 2005 37 175-179. (doi:10.1016/j.bone.2005.04.003)
23. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M & Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. Journal of Biological Chemistry 2000 275 18664-18669. (doi:10.1074/jbc.M001615200)
24. Mercado M, González B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL & Sosa E. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 3411-3415. (doi:10.1210/jc.2008-0391)
25. Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, Epaminonda P, Coletti F, Beck-Peccoz P, Spada A et al. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clinical Endocrinology 2010 72 661-667. (doi:10.1111/j.1365-2265.2009.03703.x)
26. Padova G, Borzi G, Incorvaia L, Siciliano G, Migliorino V, Vetri M & Tita P. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clinical Cases in Mineral and Bone Metabolism 2011 8 37-43.
27. Halse J & Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta Endocrinologica 1980 94 459-467. (Pubitemid 11200999)
28. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F & Lucas T. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcified Tissue International 1993 52 419-421. (doi:10.1007/BF00571329)
29. De la Piedra C, Larrañaga J, Castro N, Horcajada C, Rapado A, Herrera Pombo JL & Carbó E. Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcified Tissue International 1988 43 44-45. (doi:10.1007/BF02555167)
30. Ezzat S, Melmed S, Endres D, Eyre DR & Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. Journal of Clinical Endocrinology and Metabolism 1993 76 1452-1457. (doi:10.1210/jcem76.6.8501150)
31. Ueland T, Fougner SL, Godang K, Schreiner T & Bollerslev V. Serum Gh and IGF1 are significant determinants of bone turn over but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. European Journal of Endocrinology 2006 155 709-715. (doi:10.1530/eje.1.02285)
32. Wassenaar MJ, Biermasz NR, Hamdy NA, Zillikens MC, van Meurs JB, Rivadeneira F, Hofman A, Uitterlinden AG, Stokkel MP, Roelfsema F et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. European Journal of Endocrinology 2011 164 475-483. (doi:10.1530/EJE-10-1005)
33. Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L & Giustina A. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 2011 40 102-108. (doi:10.1007/s12020-011-9486-x)
34. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA & Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013 16 294-302. (doi:10.1007/s11102-012-0420-x)
35. Mazziotti G, Bilezikian J, Canalis E, Cocchi D & Giustina A. New under standing and treatments for osteoporosis. Endocrine 2012 41 58-69. (doi:10.1007/s12020-011-9570-2)
36. Brzana J, Yedinak CG, Hameed N & Fleseriu M. FRAX score in acromegaly: does it tell the whole story? Clinical Endocrinology 2014 80 614-616. (doi:10.1111/cen.12262)
37. Madeira M, Neto LV, de Paula Paranhos Neto F, Barbosa Lima IC, Carvalho de Mendonça LM, Gadelha MR & Fleiuss de Farias ML. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. Journal of Clinical Endocrinology and Metabolism 2013 98 1734-1741. (doi:10.1210/jc.2012-4073)
38. Gola M, Bonadonna S, Doga M & Giustina A. Clinical review: Growth hormone and cardiovascular risk factor. Journal of Clinical Endocrinology and Metabolism 2005 90 1864-1870. (doi:10.1210/jc.2004-0545)
39. Diamond T, Nery L & Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Annals of Internal Medicine 1989 111 567-573. (doi:10.7326/0003-4819-111-7-567)
40. Battista C, Chiodini I, Muscarella S, Guglielmi G, Mascia ML, Carnevale V & Scillitani A. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clinical Endocrinology 2009 70 378-382. (doi:10.1111/j.1365-2265.2008.03322.x)
41. Madeira M, Neto LV, de Lima GA, Moreira RO, de Mendonça LM, Gadelha MR & Farias ML. Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporosis International 2010 21 2019-2025. (doi:10.1007/s00198-009-1165-x)
42. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A & Giorgino F. The GH/IGF1 axis and signaling pathway in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. Journal of Endocrinology 2010 205 201-210. (doi:10.1677/JOE-09-0431)
43. Berryman DE, Christiansen JS, Johannsson G, Thorner MO & Kopchick JJ. Role of the GH/IGF1 axis in lifespan and healthspan: lessons from animal models. Growth Hormone & IGF Research 2008 18 455-471. (doi:10.1016/j.ghir. 2008.05.005)
44. Fernholm R, Bramnert M, Hagg E, Hilding A, Baylink DJ, Mohan S & Thorén M. Growth hormone replacement therapy improves body composition and increased bone metabolism in elderly patients with pituitary disease. Journal of Clinical Endocrinology and Metabolism 2000 155 4104-4112. (doi:10.1210/jcem85.11.6949)
45. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE & Kleinberg D. Growth hormone (GH) replacement therapy in adult-onset GH deficiency. Effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 2048-2056. (doi:10.1210/jc.2003- 030346)
46. Kenth G, Shao Z, Cole DE & Goodyer CG. Relationship of the human growth hormone receptor exon 3 genotype with final adult height and bone mineral density. Journal of Clinical Endocrinology and Metabolism 2007 92 725-728. (doi:10.1210/jc.2006-1695)